Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JMKX004649
- Development stage
- Preclinical
- Lead developer
- Jemincare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JMKX004649 is a small molecule inhibitor of Complement Factor B (CFB) developed by Jemincare. It is specifically designed to target the alternative complement pathway, which plays a critical role in the pathogenesis of various immune-mediated renal disorders. By inhibiting Factor B, the drug prevents the assembly of the C3 convertase (C3bBb), thereby limiting the amplification of the complement cascade and reducing the subsequent inflammatory response and tissue damage in the kidneys. The primary indications for JMKX004649 include common immune-mediated kidney diseases such as IgA nephropathy (IgAN) and potentially lupus nephritis.
02
Targets
CFB (Complement Factor B)
Beyond the preview
Go deeper on JMKX004649.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JMKX004649.